Edition:
United Kingdom

Tigenix NV (TIG.OQ)

TIG.OQ on NASDAQ Stock Exchange Global Select Market

41.98USD
25 Jul 2018
Change (% chg)

-- (--)
Prev Close
$41.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
738
52-wk High
$47.59
52-wk Low
$20.59

Latest Key Developments (Source: Significant Developments)

Takeda And Tigenix Announce Results Of Second Acceptance Period For The Voluntary And Conditional Public Takeover Bid
Friday, 6 Jul 2018 

July 6 (Reuters) - Tigenix Nv ::TAKEDA AND TIGENIX ANNOUNCE RESULTS OF SECOND ACCEPTANCE PERIOD FOR THE VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID IN RESPECT OF TIGENIX AND COMMENCEMENT OF SIMPLIFIED SQUEEZE-OUT AND INTENTION TO DELIST THE ADSS FROM NASDAQ....FOLLOWING SETTLEMENT OF SECURITIES, TAKEDA WILL OWN 96.08% OF OUTSTANDING ORDINARY SHARES.THE SQUEEZE-OUT PERIOD WILL COMMENCE TODAY, JULY 6, 2018, AND WILL EXPIRE ON JULY 26, 2018.  Full Article

Takeda says information related to its pending voluntary and conditional public takeover bid for outstanding shares and American Depositary Shares of TiGenix
Wednesday, 23 May 2018 

May 23(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it announced information related to its previously announced and ongoing tender offer in cash for all outstanding ordinary shares, warrants and American Depositary Shares(ADS) of TiGenix NV <<>> that are not yet owned by Takeda and its affiliates, in two separate, but concurrent and related offers in Belgium and in the United States, at a price of 1.78 euros per ordinary share in cash, 35.60 euros (payable in United States Dollars) per ADS in cash and an amount per warrant in cash depending on the strike price and maturity of such warrant.  Full Article

Tigenix FY Operating Loss Widens to 53.2 Million Euros
Thursday, 12 Apr 2018 

April 12 (Reuters) - TIGENIX NV ::FY OPERATING LOSS OF EUR 53.2 MILLION VERSUS LOSS OF EUR 3.0 MILLION YEAR AGO.FY REVENUE EUR 0.9 MILLION VERSUS EUR 26.8 MILLION YEAR AGO.LOSS FOR THE YEAR OF EUR 74.8 MILLION VERSUS PROFIT OF EUR 3.8 MILLION YEAR AGO.TIGENIX EXPECTS TENDER OFFER TO BE LAUNCHED BY TAKEDA DURING APRIL 2018.CASH POSITION AS OF DECEMBER 31, 2017 AMOUNTED TO EUR 34.1 MILLION.  Full Article

Tigenix Says Received Transparency Notification From Jpmorgan Chase & Co​ On Jan 16
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Tigenix Nv ::‍TRANSPARENCY NOTIFICATION PURSUANT TO ARTICLE 14 OF LAW OF MAY 2, 2007​‍.ON JANUARY 16, 2018, TIGENIX RECEIVED A TRANSPARENCY NOTIFICATION FROM JPMORGAN CHASE & CO​.‍FOLLOWING DISPOSAL OF VOTING SECURITIES ON JAN 9 JPMORGAN CHASE & CO HOLDS 1.2 MILLION VOTING RIGHTS IN CO ​.  Full Article

EU Medicines Agency Recommendations For December 2017 ‍​
Friday, 15 Dec 2017 

Dec 15 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY RECOMMENDATIONS FOR DECEMBER 2017 ‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF NOVO NORDISK'S ONCE-WEEKLY DIABETES DRUG SEMAGLUTIDE‍​.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF KYOWA HAKKO KIRIN DRUG FOR GENETIC BLOOD DISORDER XLH BUROSUMAB.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TIGENIX'S STEM CELLS TREATMENT FOR PERIANAL FISTULAS ALOFISEL.  Full Article

Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion
Friday, 15 Dec 2017 

Dec 15 (Reuters) - TIGENIX NV ::REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE.‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​.‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​.‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​.  Full Article

Tigenix Announces Grant From Mesoblast Of Exclusive Global Patent License In Local Treatment Of Fistulae
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Tigenix Nv ::MESOBLAST GRANTS TIGENIX AN EXCLUSIVE GLOBAL PATENT LICENSE TO USE ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN THE LOCAL TREATMENT OF FISTULAE (EN).AGREEMENT INCLUDES RIGHT FOR CO TO GRANT SUB-LICENSES TO AFFILIATES AND THIRD PARTIES.MESOBLAST WILL RECEIVE SINGLE DIGIT ROYALTIES ON NET SALES OF CX601.MESOBLAST WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS.  Full Article

Mesoblast Says Granted Tigenix Access To Certain Of Its Patents
Thursday, 14 Dec 2017 

Dec 15 (Reuters) - Mesoblast Ltd ::CO WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS ​.‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​.  Full Article

JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​
Saturday, 25 Nov 2017 

Nov 24 (Reuters) - Tigenix Nv :‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​.  Full Article

Tigenix announces partial conversion of bonds
Monday, 6 Nov 2017 

Nov 6 (Reuters) - TIGENIX NV : :‍ANNOUNCES CONVERSION OF EUR 7 MILLION OF COMPANY'S SENIOR UNSECURED CONVERTIBLE BONDS DUE 2018​.‍THROUGH CONVERSION, TOTAL CONVERTIBLE DEBT OUTSTANDING REDUCED FROM EUR 25 MILLION TO EUR 18 MILLION​.‍TO ISSUE 7,792,496 SHARES IN EXCHANGE FOR THE CONVERTED BONDS​.‍SHARE EXPECTED TO BE ISSUED ON OR AROUND 10 NOVEMBER 2017​.  Full Article